Cantor Fitzgerald Has Positive View of SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Soleno Therapeutics in a research report issued on Wednesday, November 5th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.17) per share for the year, up from their previous estimate of ($1.43). The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics’ FY2026 earnings at $1.81 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million for the quarter, compared to the consensus estimate of $47.46 million.

A number of other equities research analysts also recently issued reports on SLNO. Wells Fargo & Company reaffirmed an “overweight” rating and set a $106.00 price target (down previously from $123.00) on shares of Soleno Therapeutics in a research note on Wednesday. Robert W. Baird set a $121.00 target price on shares of Soleno Therapeutics and gave the company an “outperform” rating in a research report on Friday, July 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a research note on Monday, August 18th. Finally, Cowen restated a “buy” rating on shares of Soleno Therapeutics in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $114.50.

Soleno Therapeutics Trading Up 9.6%

SLNO stock opened at $47.70 on Friday. The firm has a fifty day moving average price of $62.30 and a 200 day moving average price of $72.92. Soleno Therapeutics has a fifty-two week low of $41.50 and a fifty-two week high of $90.32. The firm has a market cap of $2.54 billion, a PE ratio of -11.52 and a beta of -2.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13.

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. Raymond James Financial Inc. bought a new stake in Soleno Therapeutics in the second quarter worth about $25,000. Nisa Investment Advisors LLC raised its holdings in shares of Soleno Therapeutics by 287.8% in the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares during the period. AlphaQuest LLC raised its holdings in shares of Soleno Therapeutics by 37.5% in the first quarter. AlphaQuest LLC now owns 983 shares of the company’s stock worth $70,000 after buying an additional 268 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after acquiring an additional 423 shares during the last quarter. Finally, KBC Group NV purchased a new position in Soleno Therapeutics during the 2nd quarter valued at $77,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.